Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-2...
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-2...